Humoral immune response to the capsid components of recombinant adenoviruses: routes of immunization modulate virus-induced Ig subclass shifts.
This study examines in detail the capsid-specific humoral immune response of BALB/c mice after one single injection of a replication-defective adenovirus. Two routes of immunization, intravenous (i.v.) and intraperitoneal (i.p.), were compared for the response induced against the adenovirus particle and the three major components of the viral capsid, hexon, penton base, and fiber. A single immunization with the replication-defective adenovirus induces a long and persistent humoral response specific for the virus. However, the molecular components of the viral capsid are differentially recognized depending on the route of immunization. The sera from mice immunized i.p. recognized only the hexon protein and a preferential switch to the IgG2a subclass was obtained which remained stable 100 days post-immunization. The sera obtained from mice immunized i.v. gave a more complex response. At the beginning of the response, an isotype bias toward the IgG2a subclass was observed, but the isotype distribution changed during the whole period of the response. Neutralizing activity was maximum 45 days after immunization by both routes, and no activity was detectable after 3 months. However, the i.v. serum displayed a higher neutralizing activity than the i.p. serum. The IgM antiviral antibodies appeared to be an important component of the neutralizing activity, and the two routes of immunization do not induce the same IgG isotypes to neutralize viral infectivity. Extension of these findings to human gene therapy using recombinant adenoviruses may help to characterize the precise viral protein targets of neutralizing antibodies.
Gahéry-Ségard
H
H
Laboratoire d'Immunologie des Pathologies Infectieuses et Tumorales, INSERM Unité 445, Université R. Descartes, Paris, France. gahery@icgm.cochin.inserm.fr
Juillard
V
V
Gaston
J
J
Lengagne
R
R
Pavirani
A
A
Boulanger
P
P
Guillet
J G
JG
D000260:Adenoviruses, Human / Q000276:immunology*; D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis*; D000917:Antibody Formation; D000956:Antigens, Viral / Q000008:administration & dosage*; D015153:Blotting, Western; D002213:Capsid / Q000276:immunology*; D036022:Capsid Proteins; D002478:Cells, Cultured; D003673:Defective Viruses / Q000276:immunology; D005822:Genetic Vectors; D006801:Humans; D007132:Immunoglobulin Isotypes / Q000096:biosynthesis*; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D051379:Mice; D008807:Mice, Inbred BALB C; D009500:Neutralization Tests; D013997:Time Factors; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology; D015678:Viral Structural Proteins
D000914:Antibodies, Viral; D000956:Antigens, Viral; D036022:Capsid Proteins; D007132:Immunoglobulin Isotypes; D014614:Vaccines, Synthetic; D015678:Viral Structural Proteins; C018315:hexon capsid protein, Adenovirus; C043322:penton protein, adenovirus